# Evidence Summary ### Shikonin research overview 1. Shikonin has broad but still shallow oncology coverage. It appears across breast, bladder, oesophageal, ovarian, cervical, lung, liver, thyroid, and pancreatic models. Most of that evidence is still cell-line work. 2. PKM2 inhibition is the most repeated mechanism. This has been shown across multiple cancer types and more than one research group. That makes it one of the more credible parts of the story. 3. Dual cell death is the most important translational finding. Shikonin can induce apoptosis and necroptosis. That matters most in resistant disease, where apoptosis-only strategies start to fail. 4. ER-positive breast cancer has the most developed subtype-specific rationale. This is where shikonin has the clearest combined story across ERα suppression, ERα degradation, GPER downregulation, and tamoxifen synergy. 5. Combination studies usually outperform shikonin alone. Preclinical synergy has been reported with tamoxifen, cisplatin, gefitinib-related derivatives, and doxorubicin. 6. Translation is limited by formulation. Many active in vitro concentrations may not be achievable with current oral products. That is the biggest practical barrier. ### Clinical application status **Approved status:** Marketed in some supplement contexts, but not approved as a cancer therapy. **Clinical use:** Best positioned as an investigational compound, not a treatment-ready adjunct. **Evidence strength:** Strong mechanistic and preclinical interest, with no human oncology outcomes. {% stepper %} {% step %} > Shikonin has one of the more coherent preclinical profiles among plant-derived naphthoquinones. The PKM2 story is real. The ER-pathway evidence is specific. The resistance-reversal data is more than generic cytotoxicity. The limit is still decisive: human oncology evidence does not exist. The honest position today is worth tracking closely, not ready for clinical use. > {% endstep %} > {% endstepper %} ### Key advantages 1. **PKM2 relevance** — it targets a tumour-preferential glycolytic node with cross-cancer importance 2. **Necroptosis capacity** — it can bypass classical apoptosis resistance in selected models 3. **ER-pathway specificity** — it acts at receptor, membrane-signalling, and local-estrogen levels in breast-cancer models 4. **Combination logic** — several preclinical combinations show better results than shikonin alone 5. **Breadth of activity** — it spans metabolism, cell death, endocrine signalling, and microenvironment effects ### Key considerations 1. **No human oncology trials** — every anticancer claim still rests on preclinical evidence 2. **Bioavailability remains poor** — raw shikonin is hard to deliver reliably by oral use 3. **Dose translation is unresolved** — cell-line concentrations do not map cleanly onto consumer products 4. **Liver caution remains important** — quinone compounds can create oxidative stress in healthy tissue too 5. **Endocrine interaction questions remain open** — synergy with tamoxifen is promising, but human safety beside endocrine therapy is unknown ### Bottom line Shikonin is a serious preclinical compound. Its main value today is not as a supplement recommendation. It is as a mechanism-rich candidate that keeps showing up where cancer cells rely on PKM2, estrogen signalling, or apoptosis escape. ### Human evidence outside oncology Shikonin has more human-level evidence outside oncology than inside it. That still does not make the evidence strong. Most human-relevant data involve whole-herb formulas, topical preparations, ex vivo human cells, or alkannin rather than isolated shikonin.
See the full non-oncology human-evidence breakdown #### Psoriasis — strongest human signal This is the clearest clinical area. A 2022 systematic review and meta-analysis pooled 11 clinical trials with 1,024 participants using Chinese herbal formulas containing *Lithospermum erythrorhizon* as the primary herb. PSASI scores improved significantly. The limit is decisive. These were multi-herb formulas, not isolated shikonin. [Systematic review and meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC9128614/) #### Wound healing — older clinical signal An older clinical trial in 72 patients with varicose leg ulcers used topical alkannin esters. Healing results were favourable. This was alkannin, not shikonin, and it was topical only. Human skin-cell work also supports a wound-healing mechanism, with increased keratinocyte and dermal-fibroblast proliferation without excess collagen production. [Wound-healing review and clinical context](https://pmc.ncbi.nlm.nih.gov/articles/PMC4717985/) #### COPD — ex vivo human immune-cell evidence A 2020 study collected PBMCs from 10 patients with COPD and treated them ex vivo with shikonin. At non-cytotoxic concentrations, shikonin reduced LPS-induced TNF-α production and NF-κB activation. That confirms activity in human immune cells. It does not show treatment benefit in patients. [Ex vivo COPD PBMC study](https://pmc.ncbi.nlm.nih.gov/articles/PMC7480124/) #### Atopic dermatitis — small oral trial A randomised placebo-controlled trial enrolled 28 participants with atopic dermatitis and used oral gromwell extract for 10 weeks. Overall SCORAD improvement was not statistically significant. This was whole-herb extract, not standardised isolated shikonin. [Atopic dermatitis trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC4904053/) #### Hypertrophic scarring — human tissue-derived fibroblast work Shikonin reduced collagen overproduction and increased apoptosis in hypertrophic scar-derived human fibroblasts. This is more translatable than standard immortalised cell-line work. It is still in vitro. [Human fibroblast study](https://www.sciencedirect.com/science/article/abs/pii/S0009279715000034) #### Anti-HIV — in vitro human-cell evidence Shikonin inhibits HIV-1 reverse transcriptase and has shown strong inhibition of viral invasion in vitro at non-cytotoxic concentrations. There is no clinical HIV evidence. [Review including anti-HIV data](https://pmc.ncbi.nlm.nih.gov/articles/PMC10745356/) #### Immune diseases more broadly — still preclinical Multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, asthma, and type 1 diabetes remain preclinical topics. The recurring mechanisms are NF-κB suppression, NLRP3 modulation, and macrophage polarisation. No clinical trials with isolated shikonin were reported. [Immune-disease review](https://pubmed.ncbi.nlm.nih.gov/37454591/) #### What this means for oncology The main takeaway is mechanistic, not clinical. Human psoriasis data and ex vivo COPD data support that shikonin-related anti-inflammatory effects are not just theoretical. NF-κB and TNF-α suppression appear to operate in human-relevant systems. That strengthens the broader biology. It does not close the oncology gap. There are still no human cancer trials, and no established systemic dose for cancer use.
### Key references Ahmad F et al. (2024). Shikonin in breast cancer treatment: a comprehensive review. *Journal of Pharmacy and Pharmacology.*\ Lv C et al. (2021). Shikonin inhibits tumour growth of ESCC by suppressing PKM2 and aerobic glycolysis. *Journal of Cancer.*\ Li Z et al. (2018). PKM2 inhibitor shikonin overcomes cisplatin resistance in bladder cancer. *PMC.*\ Yang J et al. (2019). ER-mediated anti-tumor effects of shikonin on breast cancer. *European Journal of Pharmacology.*\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/evidence-summary.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.